Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caron A Jacobson

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Journal of the American Society of Nephrology : JASN|April 21, 2026
eGFR Discordance and its Association with Outcomes following Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell TherapiesApi Chewcharat, Rajesh Anumolu, Aditya Suresh, et al.
Blood Advances|September 3, 2021
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2011
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantationCaron A Jacobson, Amin T Turki, Sean M McDonough, et al.
Blood|June 2, 2016
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L Lampson, Siddha N Kasar, Tiago R Matos, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
Transplantation and Cellular Therapy|May 24, 2022
Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United StatesCaron A Jacobson, Frederick L Locke, Long Ma, et al.
Leukemia & Lymphoma|February 21, 2024
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOPRonald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, et al.
Blood|May 27, 2021
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucelVicki Plaks, John M Rossi, Justin Chou, et al.
Leukemia & Lymphoma|August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantationEleanor Taranto, Robert Redd, Erin Jeter, et al.
Nature Medicine|August 29, 2022
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphomaNathalie Scholler, Regis Perbost, Frederick L Locke, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Journal of the American Society of Nephrology : JASN|April 21, 2026
eGFR Discordance and its Association with Outcomes following Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell TherapiesApi Chewcharat, Rajesh Anumolu, Aditya Suresh, et al.
Blood Advances|September 3, 2021
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2011
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantationCaron A Jacobson, Amin T Turki, Sean M McDonough, et al.
Blood|June 2, 2016
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L Lampson, Siddha N Kasar, Tiago R Matos, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
Transplantation and Cellular Therapy|May 24, 2022
Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United StatesCaron A Jacobson, Frederick L Locke, Long Ma, et al.
Leukemia & Lymphoma|February 21, 2024
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOPRonald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, et al.
Blood|May 27, 2021
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucelVicki Plaks, John M Rossi, Justin Chou, et al.
Leukemia & Lymphoma|August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantationEleanor Taranto, Robert Redd, Erin Jeter, et al.
Nature Medicine|August 29, 2022
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphomaNathalie Scholler, Regis Perbost, Frederick L Locke, et al.
Pageof 14